Displaying 11 - 11 of 11 for Lung
  • Redefining Therapy in Early COPD: RETHINC (H-40614)
    • This is a 12-week study to asses the efficacy and safety of indacaterol/glycopyrrolate inhaled twice daily in symptomatic current and former smokers with respiratory symptoms despite having a normal spirometry result.